Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: A systematic review and meta-analysis

AIDS

Volumn 27, Issue 3, 2013, Pages 417-425

  Druyts, Eric ^a   Dybul, Mark ^b   Kanters, Steve ^c   Nachega, Jean ^d   Birungi, Josephine ^e   Ford, Nathan ^f   Thorlund, Kristian ^g   Negin, Joel ^h   Lester, Richard ⁱ   Yaya, Sanni ^a   Mills, Edward J ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b GEORGETOWN UNIVERSITY LAW CENTER   (United States)

^c SIMON FRASER UNIVERSITY   (Canada)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e THE AIDS SUPPORT ORGANIZATION   (Uganda)

^f International Office   (Switzerland)

^g MCMASTER UNIVERSITY   (Canada)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

Author keywords

Africa; antiretroviral therapy; HIV; men; meta analysis; mortality

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; GENDER; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; PREVALENCE; PRIORITY JOURNAL; REPRODUCTIVE HEALTH; RISK ASSESSMENT; SCALE UP; SENSITIVITY ANALYSIS; SOUTH AFRICA; SYSTEMATIC REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; COHORT STUDIES; EVIDENCE-BASED MEDICINE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV SEROPOSITIVITY; HUMANS; MALE; ODDS RATIO; RISK FACTORS; SEX DISTRIBUTION;

EID: 84872363003     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328359b89b     Document Type: Article

References (52)

1. WHO, UNAIDS, UNICEF. Global HIV/AIDS Response: Epidemic update and health sector progress towards universal access. Geneva, Switzerland: World Health Organization; 2011.
2. The Global Fund to Fight AIDS TaMGF. Fighting AIDS. http://www. theglobalfund.org. [Accessed 25 March 2009].
3. The United States President's Emergency Plan for AIDS Relief (PEPFAR). http://www.pepfar.gov/. [Accessed 30 November 2011].
4. Gilks C, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-510.
5. United Nations. Political Declaration on HIV/AIDS. Resolution 60/262 adopted by the General Assembly, New York. 2006. http://www.un.org/depts/dhl/ resguide/r60.htm. [Accessed 10 January 2012].
6. Open Society Institute. What works for women and girls: evidence for HIV/AIDS interventions. New York: Open Society Institute. 2010. http://www.whatworksforwomen.org [Accessed 15 December 2011].
7. The United States President's Emergency Plan for AIDS Relief (PEPFAR). A woman and girl-centered approach to health and gender equity. http://www.pepfar.gov/strategy/ghi/134852.htm. [Accessed 5 December 2011].
8. Johannessen A. Are men the losers of the antiretroviral treatment scale-up? AIDS 2011; 25:1225-1226.
9. Cornell M, McIntyre J, Myer L. Men and antiretroviral therapy in Africa: our blind spot. Trop Med Int Health 2011; 16:828-829.
10. Braitstein P, Boulle A, Nash D, Brinkhof MW, Dabis F, Laurent C, et al. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) 2008; 17:47-55.
11. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
12. Stroup D, Berlin J, Morton S, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:2000-2012.
13. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/ oxford.asp [Accessed 15 December 2011].
14. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17:2815-2834.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
16. Fleiss J. The statistical basis of meta-analysis. Stat Methods Med Res 1993; 2:121-145.
17. Miller J. The inverse of the Freeman-Tukey Double Arcsine transformation. Am Stat 1978; 32:138.
18. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-1558.
19. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. Br Med J 2003; 327:557-560.
20. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic 2010. Geneva, Switzerland: UNAIDS; 2010.
21. United Nations development Programme. Human development report 2011. New York, NY: UNDP.
22. Alemu AW, Sebastian MS. Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia. Glob Health Action 2010; 3:5398.
23. Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, Mathee S, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 2010; 24:563-572.
24. Boyles TH, Wilkinson LS, Leisegang R, Maartens G. Factors influencing retention in care after starting antiretroviral therapy in a rural South African programme. PLoS One 2011; 6:e19201.
25. Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, Kambugu A. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 2009; 49:965-972.
26. Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, Reid SE, et al. Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune Defic Syndr 2010; 54:63-70.
27. Cornell M, Myer L, Kaplan R, Bekker LG, Wood R. The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health 2009; 14:722-731.
28. DeSilva MB, Merry SP, Fischer PR, Rohrer JE, Isichei CO, Cha SS. Youth, unemployment, and male gender predict mortality in AIDS patients started on HAART in Nigeria. AIDS Care 2009; 21:70-77.
29. Ford N, Kranzer K, Hilderbrand K, Jouquet G, Goemaere E, Vlahakis N, et al. Early initiation of antiretroviral therapy and associated reduction in mortality, morbidity and defaulting in a nurse-managed, community cohort in Lesotho. AIDS 2010; 24:2645-2650.
30. Hawkins C, Chalamilla G, Okuma J, Spiegelman D, Hertzmark E, Aris E, et al. Sex differences in antiretroviral treatment outcomes among HIV-infected adults in an urban Tanzanian setting. AIDS 2011; 25:1189-1197.
31. Johannessen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, Aglen HE, et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis 2008; 8:52.
32. MacPherson P, Moshabela M, Martinson N, Pronyk P. Mortality and loss to follow-up among HAART initiators in rural South Africa. Trans R Soc Trop Med Hyg 2009; 103:588-593.
33. Maskew M, Brennan AT, Macphail AP, Sanne IM, Fox MP. Poorer ART outcomes with increasing age at a large public sector HIV Clinic in Johannesburg, South Africa. J Int Assoc Physicians AIDS Care (Chic) 2012; 11:57-65.
34. Mills EJ, Bakanda C, Birungi J, Chan K, Hogg RS, Ford N, et al. Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda. J Int AIDS Soc 2011; 14:52.
35. Mujugira A, Wester CW, Kim S, Bussmann H, Gaolathe T. Patients with advanced HIV type 1 infection initiating antire-troviral therapy in Botswana: treatment response and mortality. AIDS Res Hum Retroviruses 2009; 25:127-133.
36. Mulissa Z, Jerene D, Lindtjorn B. Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. PLoS One 2010; 5:e13268.
37. Mutevedzi PC, Lessells RJ, Heller T, Barnighausen T, Cooke GS, Newell ML. Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: does rapid expansion affect patient outcomes? Bull World Health Organ 2010; 88:593-600.
38. Palombi L, Dorrucci M, Zimba I, Scarcella P, Mancinelli S, Buonomo E, et al. Immunologic response to highly active antiretroviral therapy and mortality reduction in a cohort of human immunodeficiency virus-positive persons in Mozambique. Am J Trop Med Hyg 2010; 83:1128-1132.
39. Peterson I, Togun O, de Silva T, Oko F, Rowland-Jones S, Jaye A, Peterson K. Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia. AIDS 2011; 25:2167-2175.
40. Sieleunou I, Souleymanou M, Schonenberger AM, Menten J, Boelaert M. Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon. Trop Med Int Health 2009; 14:36-43.
41. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, et al. Rapid scaling-up of antiretroviral therapy in 10 000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS 2008; 22:873-882.
42. van Griensven J, Zachariah R, Rasschaert F, Reid T. Discordant immunologic and virologic responses to antiretroviral therapy and associated mortality in a large treatment program in Rwanda. J Acquir Immune Defic Syndr 2009; 50:556-558.
43. Weigel R, Estill J, Egger M, et al. Mortality and loss to follow-up in the first year of art: malawi national ART programme. AIDS 2012; 26:365-373.
44. Kouanda S, Meda I, Nikiema L, et al. Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study. AIDS Care 2012; 24:478-490.
45. Borenstein M, Hedges L, Higgins JP, Rothstein H. Introduction to meta-analysis. Chichester: Wiley; 2009. pp. 312.
46. Lawn S, Harries A, Anglaret X, Myer L, Wood R. Early Mortality among adults accessing antiretroviral treatment programs in sub-Saharan Africa. AIDS 2008; 22:1897-1908.
47. Fox M, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010; 15:1-15.
48. Kuwane B, Appiah K, Felix M, Grant A, Churchyard G. Expanding HIV care in Africa: making men matter in Johannesburg. Lancet 2009; 374:1329.
49. Hoffmann CJ, Fielding KL, Johnston V, Charalambous S, Innes C, Moore RD, et al. Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr 2011; 58:269-276.
50. van der Borght SF, Clevenbergh P, Rijckborst H, Nsalou P, Onyia N, Lange JM, et al. Mortality and morbidity among HIV type-1-infected patients during the first 5 years of a multicountry HIV workplace programme in Africa. Antivir Ther 2009; 14:63-74.
51. Fitzgerald M, Collumbien M, Hosegood V. No one can ask me 'Why do you take that stuff?': men's experiences of antiretro-viral treatment in South Africa. AIDS Care 2010; 22:355-360.
52. International Labour Office. Guide to mainstreaming gender in workplace responses to HIV and AIDS. 2011. http://www.ilo. org/aids/Publications/WCMS- 165448/lang-en/index.htm.